Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 51, 3237-3242, June 15, 1991]
© 1991 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kasahara, K.
Right arrow Articles by Saijo, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kasahara, K.
Right arrow Articles by Saijo, N.

Metallothionein Content Correlates with the Sensitivity of Human Small Cell Lung Cancer Cell Lines to Cisplatin1

Kazuo Kasahara2, Yasuhiro Fujiwara, Kazuto Nishio, Tohru Ohmori, Yoshikazu Sugimoto, Kazuhide Komiya, Tamotsu Matsuda and Nagahiro Saijo3

Pharmacology Division, National Cancer Center Research Institute, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104 [K. K., Y. F., K. N., T. O., Y. S., N. S.] Department of Radiopharmacy, Hoshi University, 4-41, Ebara 2-chome, Shinagawa-ku, Tokyo, 142 [K. K.]; and third Internal Medicine, School of Medicine, Kanazawa University, Takaramachi 13-1, Kanazawa, 920 [K. K., T. M.], Japan

We have established cis-diamminedichloroplatinum(II) (cisplatin) resistant human small cell lung cancer cell lines, H69/CDDP0.2 and H69/CDDP, to investigate the mechanism of acquired resistance to cisplatin. H69/CDDP0.2 and H69/CDDP were 6- and 11-fold resistant to cisplatin compared with the H69 parental cell line. H69/CDDP was also resistant to cadmium chloride (2-fold), cis-diammine(glycolato)platinum (4-fold), 4-hydroperoxycyclophosphamide (3-fold) and 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosourea (4-fold) if the drug concentrations that inhibit cell growth by 50% from growth inhibition assay were compared. There was no significant difference in the cisplatin accumulation among these cell lines. Although DNA interstrand cross-link formations, determined by filter elution assay in H69/CDDP0.2 and H69/CDDP, was decreased to 20 to 30% of that in H69 parental cells, the repair capacity of DNA interstrand cross-links was equivalent in all three cell lines. Intracellular glutathione content was equal in all cell lines. H69/CDDP had the highest glutathione S-transferase activity (H69, 11 nmol/min/mg protein, H69/CDDP0.2, 12 nmol/min/mg protein; H69/CDDP, 74 nmol/min/mg protein, respectively) and an overexpression of glutathione S-transferase {pi} mRNA. The drug concentrations that inhibit cell growth by 50% for cisplatin in all cell lines were decreased by treatment with ethacrynic acid, an inhibitor of glutathione S-transferase {pi}, but this did not alter the relative degree of resistance. Intracellular metallothionein content (H69, 14 pmol/mg protein, H69/CDDP0.2, 22 pmol/mg protein; H69/CDDP, 33 pmol/mg protein, respectively) and expression of metallothionein mRNA were correlated with the drug concentrations that inhibit cell growth by 50% of the three cell lines for cisplatin and cadmium chloride. The present study suggested the importance of metallothionein in the mechanisms of cisplatin resistance.

1 This research was supported in part by a Grant-in-Aid from the Ministry of Health and Welfare for the Comprehensive 10-Year Strategy for Cancer Control.

2 Recipient of a research resident fellowship from the Foundation for Promotion of Cancer Research.

3 To whom requests for reprints should be addressed.

Received 11/27/90. Accepted 4/ 9/91.




This article has been cited by other articles:


Home page
Cancer Res.Home page
S. Kano, N. Miyajima, S. Fukuda, and S. Hatakeyama
Tripartite Motif Protein 32 Facilitates Cell Growth and Migration via Degradation of Abl-Interactor 2
Cancer Res., July 15, 2008; 68(14): 5572 - 5580.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
D. Pectasides, E. Pectasides, A. Psyrri, and T. Economopoulos
Treatment Issues in Clear Cell Carcinoma of the Ovary: A Different Entity?
Oncologist, November 1, 2006; 11(10): 1089 - 1094.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. Kumar Biswas, J. Huang, S. Persaud, and A. Basu
Down-regulation of Bcl-2 is associated with cisplatin resistance in human small cell lung cancer H69 cells
Mol. Cancer Ther., March 1, 2004; 3(3): 327 - 334.
[Abstract] [Full Text]


Home page
Obstet GynecolHome page
H. Itamochi, J. Kigawa, T. Sugiyama, Y. Kikuchi, M. Suzuki, and N. Terakawa
Low Proliferation Activity May Be Associated With Chemoresistance in Clear Cell Carcinoma of the Ovary
Obstet. Gynecol., August 1, 2002; 100(2): 281 - 287.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. B. Deng, H. K. Parekh, K.-C. Chow, and H. Simpkins
Increased Expression of Dihydrodiol Dehydrogenase Induces Resistance to Cisplatin in Human Ovarian Carcinoma Cells
J. Biol. Chem., April 19, 2002; 277(17): 15035 - 15043.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
P. Perego, C. Caserini, L. Gatti, N. Carenini, S. Romanelli, R. Supino, D. Colangelo, I. Viano, R. Leone, S. Spinelli, et al.
A Novel Trinuclear Platinum Complex Overcomes Cisplatin Resistance in an Osteosarcoma Cell System
Mol. Pharmacol., March 1, 1999; 55(3): 528 - 534.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
K. Ghoshal, Y. Wang, J. F. Sheridan, and S. T. Jacob
Metallothionein Induction in Response to Restraint Stress. TRANSCRIPTIONAL CONTROL, ADAPTATION TO STRESS, AND ROLE OF GLUCOCORTICOID
J. Biol. Chem., October 23, 1998; 273(43): 27904 - 27910.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1991 by the American Association for Cancer Research.